These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26022563)

  • 1. Valuing vaccines: deficiencies and remedies.
    Bloom DE
    Vaccine; 2015 Jun; 33 Suppl 2():B29-33. PubMed ID: 26022563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on the development and use of economic evidence for immunization decision-making in a developing country.
    Molina-Aguilera IB
    Vaccine; 2015 May; 33 Suppl 1():A6-7. PubMed ID: 25919176
    [No Abstract]   [Full Text] [Related]  

  • 3. Perspectives on expanding the evidence base to inform vaccine introduction: Program costing and cost-effectiveness analyses.
    Andrus JK; Walker DG
    Vaccine; 2015 May; 33 Suppl 1():A2-3. PubMed ID: 25919161
    [No Abstract]   [Full Text] [Related]  

  • 4. Foreword.
    Etienne CF
    Vaccine; 2015 May; 33 Suppl 1():A1. PubMed ID: 25919148
    [No Abstract]   [Full Text] [Related]  

  • 5. Gavi's balancing act: Accelerating access to vaccines while ensuring robust national decision-making for sustainable programmes.
    Sosler S; Kallenberg J; Johnson HL
    Vaccine; 2015 May; 33 Suppl 1():A4-5. PubMed ID: 25919172
    [No Abstract]   [Full Text] [Related]  

  • 6. The ProVac initiative and evolving decision support.
    Sanderson CF
    Vaccine; 2015 May; 33 Suppl 1():A8-10. PubMed ID: 25919181
    [No Abstract]   [Full Text] [Related]  

  • 7. A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy.
    Favato G; Baio G; Capone A; Marcellusi A; Saverio Mennini F
    Clin Ther; 2013 Jul; 35(7):904-14. PubMed ID: 23806328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ProVac Global Initiative: a vision shaped by ten years of supporting evidence-based policy decisions.
    Jauregui B; Janusz CB; Clark AD; Sinha A; Garcia AG; Resch S; Toscano CM; Sanderson C; Andrus JK
    Vaccine; 2015 May; 33 Suppl 1():A21-7. PubMed ID: 25919164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs.
    Jeuland M; Whittington D
    Vaccine; 2009 May; 27(23):3109-20. PubMed ID: 19428925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vaccination--value for money?].
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Kristiansen IS
    Tidsskr Nor Laegeforen; 2006 Oct; 126(20):2670-3. PubMed ID: 17057767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The decision making process on new vaccines introduction in South Africa.
    Ngcobo NJ; Cameron NA
    Vaccine; 2012 Sep; 30 Suppl 3():C9-13. PubMed ID: 22939028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examining the cost of delivering routine immunization in Honduras.
    Janusz CB; Castañeda-Orjuela C; Molina Aguilera IB; Felix Garcia AG; Mendoza L; Díaz IY; Resch SC
    Vaccine; 2015 May; 33 Suppl 1():A53-9. PubMed ID: 25919175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence-based decision-making for vaccine introductions: Overview of the ProVac International Working Group's experience.
    Jauregui B; Garcia AG; Bess Janusz C; Blau J; Munier A; Atherly D; Mvundura M; Hajjeh R; Lopman B; Clark AD; Baxter L; Hutubessy R; de Quadros C; Andrus JK
    Vaccine; 2015 May; 33 Suppl 1(0 1):A28-33. PubMed ID: 25919170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination planning in Italy: increasing vaccines while reducing coverage?
    Garattini L; Curto A; Freemantle N
    Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):547-548. PubMed ID: 27441592
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
    Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Evaluation of Vaccines: Belgian Reflections on the Need for a Broader Perspective.
    Annemans L; Beutels P; Bloom DE; De Backer W; Ethgen O; Luyten J; Van Wilder P; Willem L; Simoens S
    Value Health; 2021 Jan; 24(1):105-111. PubMed ID: 33431141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Social Value Of Vaccination Programs: Beyond Cost-Effectiveness.
    Luyten J; Beutels P
    Health Aff (Millwood); 2016 Feb; 35(2):212-8. PubMed ID: 26858372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs.
    Isidean SD; Tota JE; Gagnon JA; Franco EL
    Expert Rev Vaccines; 2015 Jan; 14(1):119-33. PubMed ID: 25266065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
    Brenzel L
    Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.